Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors
10.12092/j.issn.1009-2501.2024.01.009
- Author:
Quanming ZHAO
1
;
Mandou YANG
1
;
Yibo HU
1
;
Youtong SU
1
;
Li PU
1
;
Yu ZHANG
1
;
Wenliang LI
1
Author Information
1. Department of Gastric and Small Intestinal Surgery, The Third Affiliated Hospital of Kunming Medical University
- Publication Type:Journal Article
- Keywords:
drug resistance mechanisms;
drug therapy;
research progress;
stromal tumors of the gastrointestinal tract
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(1):82-89
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal-derived tumors of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) are the cornerstone of GIST therapy, but mutations in resistance genes pose many problems for treatment, especially the heterogeneity of KIT resistance mutations. In recent years, with the release of a number of GIST related drug research and experimental results, the great potential of targeted therapy, immunotherapy and combination therapy to treat GIST in different directions has been revealed, providing more therapeutic directions for GIST. This article will review the experimental research and future direction in recent years.
